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Abstract
Introduction: Acute myopathy caused by oral corticosteroids is rare. We present a case of myopathy occurring
after two doses of methylprednisolone. Typically, acute steroid myopathy occurs with therapy using intravenous
corticosteroids at high doses. Acute myopathy developing very early in the course of treatment with oral
corticosteroids has been reported only once in the literature. Corticosteroid therapy may be complicated by
myopathy, usually chronic, after prolonged high-dose therapy. Acute myopathy caused by exogenous
corticosteroids is rare, usually with intravenous corticosteroids at high doses.
Case presentation: A 49-year-old Caucasian man developed acute myopathy after taking oral methylprednisolone
for only two days, 24 mg on day 1 and 20 mg on day 2. He discontinued the medication because of new-onset
myalgias and lethargy on day 3 and was seen in our clinic four days after beginning therapy. He completely
recovered in four weeks by discontinuing the corticosteroids.
Conclusion: Among the many complications of corticosteroid therapy, acute myopathy is very rare. It requires
prompt recognition and adjustment of therapy.
Introduction
In 1932, Cushing [1] described myopathy as a clinical
feature of hypercortisolism. Corticosteroids were intro-
duced into clinical practice in 1948, and in 1958, Dubois
[2] reported the first patient with myopathy resulting
from iatrogenic corticosteroids. Since corticosteroid
therapy’s introduction into clinical practice, both acute
and chronic steroid myopathies have been well
recognized.
Chronic steroid myopathy is more common and
develops after prolonged usage of steroids [3,4]. Acute
steroid myopathy (ASM) is less common and develops
early in the course of treatment, typically with high-dose
intravenous (IV) steroids [4].
Earlier case reports of ASM usually involved patients
with asthma receiving high-dose IV corticosteroids for sta-
tus asthmaticus [5,6]. MacFarlane and Rosenthal [5]
reported a case of a patient receiving IV hydrocortisone
and developing myopathy manifested as difficulty weaning
from a ventilator. Acute myopathy developing from oral
corticosteroid has not been often reported. Kumar [7]
described a patient developing myopathy after one dose of
oral corticosteroid therapy. We report a similar case in
which the patient developed acute myopathy after two
doses of methylprednisolone.
Case presentation
A 49-year-old Caucasian man presented to the local
orthopaedic clinic with complaints of pain in the sole of
his foot. He was diagnosed with plantar fascitis and was
given a prescription for a methylprednisolone dose pack.
He complained of vague neck pain on day 2 of therapy.
Initially, he ignored the symptoms, but his condition
continued to escalate in a generalized fashion. On day 3
of therapy, myalgia and muscle weakness progressed to
involve upper arm and thigh muscles, and he did not
take the methylprednisolone dose. He was seen on day
4 of therapy by which time his symptoms had pro-
gressed to generalized muscle weakness and pain. He
stated that he was unable to open his car door because
of hand weakness. He also complained of myalgias
involving the same muscle groups. He was tender to
palpation, and his symptoms did not improve with 500
mg of over-the-counter acetaminophen, which he was
taking every six hours. He had no fever, difficulty
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breathing, flu like symptoms, facial muscle weakness,
difficulty swallowing, or urinary or gastrointestinal
symptoms. Before the current illness, his medical history
was significant for gastroesophageal reflux disease.
On examination, his vital signs included blood pres-
sure of 130/85 mm Hg, pulse of 80 beats/min, respira-
tory rate of 15 breaths/min, temperature of 98.9°F and
oxygen saturation of 98% on room air by pulse oxime-
try. There was pain on palpation of the upper and lower
extremity musculature, including the small muscles of
the hand. Sensation in cranial and peripheral nerve dis-
tribution was normal and symmetric bilaterally. Muscle
strength was 2 of 5 in the flexor and extensor groups of
the upper and lower extremities. Facial muscle strength
was normal. His hand grip was weak, and he had diffi-
culty standing up from a sitting position. His gait was
normal.
Normal deep tendon reflexes were noted. Babinski’s
sign was absent. He had normal cardiovascular, respira-
tory and abdominal examination results.
On laboratory examination, the patient had levels as
follows: creatinine phosphokinase (CPK) of 891 U/L
(reference range, 22-198 U/L), alkaline phosphatase
(ALP) of 77 IU/L (reference range, 30-120 IU/L), aspar-
tate aminotransferase (AST) of 64 U/L (reference range,
10-40 IU/L), alanine aminotransferase (ALT) of 69 IU/L
(reference range, 9-60 IU/L, C-reactive protein (CRP) of
14.86 mg/L (reference range, <5 mg/L), and erythrocyte
sedimentation rate (ESR) of 10 mm/hr (reference range,
Age/2). Muscle biopsy and electromyography (EMG)
were not performed. A basic metabolic panel and com-
plete blood count results were normal.
He was sent home with ibuprofen 400 mg every six
hours as needed for myalgias and instructions to call if
his symptoms worsened. He was seen at a one-week
scheduled return visit and reported significant improve-
ment in muscle strength and decreased pain. Examina-
tion showed muscle strength of 5 of 5 in all muscle
groups. Laboratory examination showed a CPK of
130 U/L, ALT of 82 IU/L and AST of 44 U/L. Urine
myoglobin results were negative.
He was seen again 30 days after initial presentation
and was feeling fine and had resumed his normal active
lifestyle, farming. He continues to complain of intermit-
tent foot pain, which is worse with activity, and he takes
ibuprofen 400 mg as needed for relief.
Discussion
ASM is rare and poorly understood. Several theories
have been proposed to explain the pathogenesis of this
condition. One model proposes activation of ubiquitin-
dependent proteolytic systems [8]. Another model sug-
gests that insulin-like growth factor-1, which may act as
anti-apoptotic, is inhibited by steroids, thus allowing
increased muscle apoptosis [9].
Askari et al. [10] recognized ASM in six of eight
patients who were receiving oral prednisone therapy
between July 1972 and November 1973. One patient
developed symptoms of ASM within a few days of start-
ing therapy. Five patients tolerated a low maintenance
dose of prednisone (15 to 60 mg) for a duration of 60 to
240 days without any signs or symptoms of myopathy.
However, increasing the maintenance dose resulted in
the appearance of symptoms of corticosteroid myopathy
within 30 days in four of five patients. The group con-
cluded that the development of myopathy in patients
receiving corticosteroid therapy is not related to the age
of the patient, the magnitude of the dose given or the
duration of maintenance therapy [10].
Typical presentations include diffuse myalgias and
muscle weakness. Pelvic girdle muscle involvement is
most consistently seen [10]. Some patients present with
difficulty weaning from mechanical ventilators [5,6]. Our
patient received methylprednisolone, and he was not on
any maintenance corticosteroid therapy. He did have
pelvic girdle muscle weakness, but his symptoms were
not limited to these muscle groups.
A number of laboratory investigations may aid in the
diagnosis of ASM. These include serum markers such as
CPK, AST and ALT and urine markers, including urine
myoglobin. EMG and muscle biopsy may also be helpful.
No single test is diagnostic for this condition. The diag-
nosis always involves a high degree of clinical suspicion
with diagnostic tests as an adjunct.
Serum marker elevation is an inconsistent finding.
Our patient, including other reported cases [6,7], had
elevated CPK, AST and ALT. Askari et al. [10] did not
find CPK elevation as a consistent finding in their
reported cases. They did find increased urinary creati-
nine excretion to be more consistently abnormal than
elevated CPK [10].
EMG may be normal, but abnormal EMG findings
classically include normal sensory and motor conduction
velocities with decreased amplitude of muscle action
potential [11]. We did not obtain EMG in our patient.
Typically, muscle biopsy shows diffuse necrosis of both
type I and type II fibers [6,11]; however, muscle biopsy
is often diagnostically unhelpful [10].
Currently, there are no dosing recommendations for
steroids that could decrease the likelihood of developing
myopathy. Our patient received two doses of methyl-
prednisolone, 24 mg and 20 mg. The only similar report
involved a patient taking 40 mg of prednisone [7]. We
were unable to find literature reports of patients devel-
oping myopathy while taking doses less than 40 mg of
prednisone.
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There is no specific treatment available for this condi-
tion. The most consistent finding on literature review is
the fact that myopathy resolves without any intervention
with discontinuation of steroid therapy.
Conclusion
Steroids, as a class, are well recognized as a critical
treatment modality for a number of conditions. They
are prescribed by physicians belonging to almost all
areas of medicine. Although very rare, ASM needs to be
recognized early to ameliorate its significant effects.
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